Table 2:
Objective response rate, best overall response, and disease control rate per investigator and BICR assessments in patients with metastatic or recurrent colorectal cancer locally assessed as dMMR/MSI-H
| Patients, n (%) | dMMR/MSI-H per local assessment (N=74) |
dMMR/MSI-H per central assessment (N=53) |
||
|---|---|---|---|---|
| Investigator | BICR | Investigator | BICR | |
| 19 (35·8) | 19 (35·8) | |||
| Objective response rate | 23 (31·1) | 24 (32·4) | ||
| [95% CI] | [20·8–42·9] | [22·0–44·3] | ||
| [23·1–50·2] | [23·1–50·2] | |||
| Best overall response | ||||
| Complete response | 0 | 2 (2.7) | 0 | 1 (1·9) |
| Partial response | 23 (31·1) | 22 (29·7) | 19 (35·8) | 18 (34·0) |
| Stable disease | 28 (37·8) | 25 (33·8) | 20 (37·0) | 19 (35·8) |
| Progressive disease | 19 (25·7) | 21 (28·4) | 11 (20·8) | 12 (22·6) |
| Not determined | 4 (5·4) | 4 (5·4) | 3 (5·7) | 3 (5·7) |
| Disease control for ≥12 | ||||
| 51 (68·9) | 47 (63·5) | 39 (73·6) | 37 (69·8) | |
| weeks | ||||
| [57·1–79·2] | [51·5–74·4] | |||
| [95% CI] | ||||
| [59·7–84·7] | [55·7–81·7] | |||
BICR=blinded independent central review; dMMR/MSI-H=DNA mismatch repair deficient/microsatellite instability–high.